Dejvid Veizaj

Dejvid Veizaj

Auto-generated profile, based on publicly available information

Dejvid Veizaj

Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
DVDejvid Veizaj
Dejvid Veizaj
PEPaul L. Den Exter
Paul L. Den Exter
Mettine BosMettine Bos
Mettine Bos

23 May 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
DVDejvid Veizaj
Dejvid Veizaj
DPDavid A. Poole
David A. Poole
KCKa Lei Cheung
Ka Lei Cheung
JFJos V. Flier
Jos V. Flier
PRPieter H. Reitsma
Pieter H. Reitsma
Mettine BosMettine Bos
Mettine Bos

12 February 2025 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
VSViola J.F. Strijbis
Viola J.F. Strijbis
KCKa Lei Cheung
Ka Lei Cheung
DVDejvid Veizaj
Dejvid Veizaj
TRTessa Rutten
Tessa Rutten
BBBoris de Bruin
Boris de Bruin
Mettine BosMettine Bos
Mettine Bos
Direct anticoagulants inhibit coagulation serine proteases by reversibly engaging their active site with high affinity. By modifying the S4 active site subpocket of factor (F)Xa, we introduced inhibitor resistance while preserving catalytic activity. Given the homology between FXa and thrombin in active site architecture and direct anticoagulant binding, we have targeted the S4 subsite to introduce inhibitor resistance in (pro)thrombin. Recombinant prothrombin variants were generated in which I174 was substituted or sequence R92-N98 was exchanged with that of human kallikrein-3. Specific prothrombin clotting activity of the variants was 6-fold (intrinsic clotting) to 10-fold (extrinsic clotting) reduced relative to wild-type prothrombin. Further analyses revealed that modification of the S4 subsite hampers fibrinogen and thrombomodulin-mediated protein C conversion by thrombin. Consistent with this, the thrombin variants displayed a reduced catalytic efficiency toward the peptidyl substrate used in thrombin generation assessments. The variants displayed a 2-fold reduced sensitivity for dabigatran relative to wild-type prothrombin, while argatroban inhibition was unaffected. Analyses using a purified component system revealed an up to 24-fold and 4-fold reduced IC50 for inhibition of thrombin by dabigatran and argatroban, respectively. Molecular dynamics (MD) simulations of both dabigatran-bound and unbound (apo) modified thrombin variants indicated these to comprise a larger inhibitor binding pocket relative to wild-type thrombin and display reduced inhibitor binding. As a net effect, (pro)thrombin variants with S4 subsite modifications supported detectable fibrin formation at therapeutic dabigatran concentrations. Our findings provide proof-of-concept for the engineering of thrombin variants that are resistant to direct thrombin inhibitors by modulating the S4 subsite.